A First‐in‐human, Single and Multiple Dose Study of Lunsekimig, a Novel Anti‐tslp/anti‐il‐13 NANOBODY® Compound, in Healthy Volunteers

Annemie Deiteren, Lieselot Bontinck,Griet Conickx, Marie Vigan, Nele Dervaux, Matthieu Gassiot, Selcuk Bas,Benjamin Suratt,Heribert Staudinger,Emmanuel Krupka

Clinical and Translational Science（2024）

Cited 2|Views1

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined